Oana S.
- Country
- Romania
- Department
- 3002: Hematology
Research Overview
- Long-term Safety of Asciminib in Patients With Philadelphia Chromosome-Positive CML or ALL Continuing From Parent Studies
- Evaluation of Tafasitamab and Lenalidomide Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Ineligible for HDC/ASCT
- Evaluation of Tolerability and Efficacy of Asciminib Hydrochloride Versus Nilotinib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Data & Insights
Has run more than one trial at 50 of 136 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating hematologic malignancies, with particular emphasis on blood-based cancers and lymphomas.
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Chronic Myeloid Leukemia
The investigator's work encompasses novel therapeutic approaches for patients with relapsed or refractory conditions.
Targeted Therapies
Focuses on implementing innovative targeted treatments for blood cancers, including:
- Combination therapy approaches
- Philadelphia chromosome-positive conditions
- Novel therapeutic agents
Expertise includes evaluating treatment tolerability and efficacy in adult patients with various hematologic conditions.
Treatment Development
Specializes in advancing therapeutic options for patients who have limited treatment alternatives, particularly those with:
- Refractory blood cancers
- Newly diagnosed leukemia
- Advanced stage lymphomas
The investigator's work focuses on improving outcomes for patients who are not eligible for conventional treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.